Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (5y) (2015 - 2025)
Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 37.40% |
| Sep 30, 2025 | 16.35% |
| Jun 30, 2025 | 15.86% |
| Mar 31, 2025 | -16.64% |
| Dec 31, 2024 | -38.58% |
| Sep 30, 2024 | -38.26% |
| Jun 30, 2024 | -23.62% |
| Mar 31, 2024 | -20.75% |
| Dec 31, 2023 | 14.04% |
| Sep 30, 2023 | -23.39% |
| Jun 30, 2023 | -17.83% |
| Mar 31, 2023 | -9.06% |
| Dec 31, 2022 | 1.56% |
| Sep 30, 2022 | -21.10% |
| Jun 30, 2022 | -17.61% |
| Mar 31, 2022 | -20.39% |
| Dec 31, 2021 | -19.25% |
| Sep 30, 2021 | -42.72% |
| Jun 30, 2021 | -5.39% |
| Mar 31, 2021 | -16.27% |